Clinical Trial

Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is a Phase 1/2, first-in-human, open-label, dose-escalating trial designed to assess the safety and efficacy of VNX-101 in patients with relapsed or refractory CD19-positive hematologic malignancies.
Protocol Amendment History 13 amendments
This ClinicalTrials.gov record has been amended 13 times since 2024-07-29; most recent amendment 2026-03-24.
Status change: Not Yet Recruiting → Recruiting 2024-10-15
Trial Details
NCT Number NCT06533579
Lead Sponsor Vironexis Biotherapeutics Inc.
Conditions B-cell Acute Lymphoblastic Leukemia, Large B-cell Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Marginal Zone Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Diffuse Large B Cell Lymphoma +5 more
Enrollment 32 participants
Start Date 2025-05-30
Primary Completion 2027-06 (estimated)
Study Completion 2031-09 (estimated)
Updated on ClinicalTrials.gov 2026-08-06